BioNotebook: After selling to Actelion, entrepreneur Tullman starts new company, and Revance, Dicerna, UniQure file for IPOs
This article was originally published in Scrip
Steve Tullman, the serial biopharma entrepreneur who sold companies to Actelion, Allergan and Cephalon in the past few years, is starting a new company, Alexar Therapeutics. Malvern, Pennsylvania-based Alexar is being formed with $21.5 million in financing raised by Mr Tullman’s firm NeXeption. In September, another Tullman company, Ceptaris Therapeutics, was sold to Actelion for $250 million.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.